Clinical trial
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
NCT00360737 · Emergent BioSolutions, Industry · Completed
Key facts
| NCT number | NCT00360737 |
|---|---|
| Title | Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses |
| Official title | Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018) |
| Lead sponsor | Emergent BioSolutions, Industry |
| Collaborators | Department of Health and Human Services U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) |
| Enrollment | 40 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Apr 1, 2010 |
| First posted | Aug 7, 2006 |
| Last update posted | Mar 18, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: